DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients
10 mai 2021 07h50 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
10 mai 2021 07h05 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
25 mars 2021 09h01 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Doses First Participants in TCOM Study
18 mars 2021 07h05 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update
17 mars 2021 07h05 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
04 mars 2021 16h05 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock
18 févr. 2021 16h05 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock
17 févr. 2021 16h13 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
16 févr. 2021 07h35 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
DiffusionInc_white background.jpg
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million
11 févr. 2021 22h02 HE | Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company...